NASDAQ: CLGNCollplant Biotechnologies Ltd Stock
$2.42+0.00 (+0%)
Updated Apr 17, 2025
CLGN Price
$2.42
Fair Value Price
-$0.12
Market Cap
$27.72M
52 Week Low
$2.20
52 Week High
$6.75
P/E
-1.67x
P/B
2.06x
P/S
80.07x
PEG
N/A
Dividend Yield
N/A
Revenue
$515.00k
Earnings
-$16.61M
Gross Margin
-215.5%
Operating Margin
-3,349.71%
Profit Margin
-3,225%
Debt to Equity
0.39
Operating Cash Flow
-$14M
Beta
0.47
Next Earnings
May 27, 2025
Ex-Dividend
N/A
Next Dividend
N/A
CLGN Overview
CollPlant Biotechnologies Ltd., a regenerative and aesthetic medicine company, focuses on three-dimensional (3D) bioprinting of tissues and organs, and medical aesthetics in the United States, Canada, and Europe. Its products are based on recombinant type I human collagen that is produced with its proprietary plant based genetic engineering technology. The company's products include BioInks for 3D printing of tissues and organs; dermal filler and soft tissue fillers for treating wrinkles; 3D Bioprinted breast implants for regeneration of breast tissue; injectable implants to promote breast tissue regeneration; 3D bioprinted regenerative soft tissue matrix; VergenixSTR, a soft tissue repair matrix intended for the treatment of tendinopathy; and VergenixFG, an advanced wound care product for the treatment of deep surgical incisions and wounds, including diabetic ulcers, venous and pressure ulcers, burns, bedsores, and other chronic wounds. It has collaboration agreements with 3D Systems Corporation; CellInk, a BICO Group company; Advanced Regenerative Manufacturing Institute; RegenMed Development Organization; Israel's Technion Institute of Technology; AbbVie; and STEMCELL. The company was formerly known as CollPlant Holdings Ltd. and changed its name to CollPlant Biotechnologies Ltd. in June 2019. CollPlant Biotechnologies Ltd. was founded in 2004 and is headquartered in Rehovot, Israel.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine CLGN's potential to beat the market
- CLGN doesn't meet the minimum data requirements for our proprietary Zen Ratings model. Learn more about Zen Ratings.
Zen Rating Component Grades
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
CLGN
RankedUnranked of 463
RankedUnranked of 463
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $2.61 | A | |
| $7.75 | A | |
| $16.85 | A |
Be the first to know about important CLGN news, forecast changes, insider trades & much more!
CLGN News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how CLGN scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
CLGN ($2.42) is overvalued by 2,050.17% relative to our estimate of its Fair Value price of -$0.12 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
CLGN ($2.42) is not significantly undervalued (2,050.17%) relative to our estimate of its Fair Value price of -$0.12 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
CLGN is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more CLGN due diligence checks available for Premium users.
Valuation
CLGN fair value
Fair Value of CLGN stock based on Discounted Cash Flow (DCF)
Price
$2.42
Fair Value
-$0.12
Undervalued by
2,050.17%
CLGN ($2.42) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
CLGN ($2.42) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
CLGN is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
CLGN price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-1.67x
Industry
-177.72x
Market
27.98x
CLGN price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
2.06x
Industry
4.05x
CLGN is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
CLGN's financial health
Profit margin
Revenue
$164.0k
Net Income
-$3.9M
Profit Margin
-2,364.6%
CLGN's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
CLGN's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$18.7M
Liabilities
$5.2M
Debt to equity
0.39
CLGN's short-term assets ($13.18M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
CLGN's short-term assets ($13.18M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
CLGN's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
CLGN's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$3.5M
Investing
-$58.0k
Financing
$0.0
CLGN's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
CLGN vs Biotech Stocks
Collplant Biotechnologies Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.